Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosiporfin sodium (DVDMS) photodynamic therapy versus physician's choice for locally recurrent or metastatic esophageal cancer
ChiCTR2500099425Phase 3Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cosiporfin sodium in esophageal cancer and esophagogastric junction cancer (5 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate of intraluminal target lesions. Started Mar 2025; status: completed.
02
Drugs
cosiporfin sodium
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2500099425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099425.